Skip to content

SYNERGIC-2: A Home-based Personalized Multidomain RCT from the Canadian Therapeutic Platform for Multidomain Interventions to Prevent Dementia

Cognitive Impairment | Dementia | Prevention | MCI

SYNERGIC-2 is the first large Canadian clinical trial using a 12-month home-based personalized multidomain lifestyle intervention to improve cognition in 550 older adults with Mild Cognitive Impairment (MCI), a pre-dementia state. This personalized intervention targets 5 domains, including physical exercise, cognitive training, diet recommendations, sleep interventions, and vascular risk factor management, which are all delivered using a digital platform. This will be compared to the effects of an online educational program. Both interventions are part of the Canadian Dementia Research Strategy.

null

Participation Requirements

  • Sex:

    Any
  • Eligible Ages:

    60 to 85

Participation Criteria

Inclusion Criteria:
Participants must meet all the following inclusion criteria to be eligible for enrollment:
1. 60-85 years of age.
2. Have mild cognitive impairment (MCI).
3. Have 1 or more of the following additional dementia risk factors: low physical activity, poor diet, sleep problems, and vascular-metabolic risk including diabetes, high blood pressure, high cholesterol, obesity, and smoking.
4. Have access to a home computer/laptop/tablet with stable internet and ability to use technology.
5. Proficiency in speaking and understanding written and spoken English.
6. Have normal/corrected to normal vision in at least one eye to identify stimuli on computer/tablet screen.
7. Have sufficient hearing ability.
8. Able to comply with virtual visits, treatment plan, and trial procedures and safety instructions to participate in the study’s exercise training.
Exclusion Criteria:
Participants must NOT meet any of the following exclusion criteria to be eligible for enrollment:
1. Have a diagnosis of dementia.
2. Any underlying severe disease that would interfere with study activities/intervention engagement.
3. Have had surgery within the last 2 months or having an upcoming planned surgery in the next 12 months that could interfere with vision, hearing, mobility, or any other abilities to participate in the study.
4. Regular use of Benzodiazepine or neuroleptic drugs that may interfere with ability to participate in study assessments and interventions.
5. Recent (in the past 12 months) and/or current substance or alcohol abuse.
6. Have had a heart attack within the past 6 months.
7. Intention to enroll in other interventional clinical trials during same time.

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Krista Nelles

null
780-248-2043
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00130655